Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally
administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of
recurrent pediatric solid tumors including but not limited to neuroblastoma,
rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma